{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:36:21Z","timestamp":1793039781299,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["POCI\/01\/0145\/FEDER\/007265"],"award-info":[{"award-number":["POCI\/01\/0145\/FEDER\/007265"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003381","name":"Minist\u00e9rio da Educa\u00e7\u00e3o e Ci\u00eancia","doi-asserted-by":"publisher","award":["PT2020 UID\/QUI\/50006\/2013"],"award-info":[{"award-number":["PT2020 UID\/QUI\/50006\/2013"]}],"id":[{"id":"10.13039\/501100003381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007395","name":"Instituto Nacional de Ci\u00eancia e Tecnologia para Excitotoxicidade e Neuroprote\u00e7\u00e3o","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.lfs.2019.117093","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T02:30:57Z","timestamp":1574303457000},"page":"117093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges"],"prefix":"10.1016","volume":"240","author":[{"given":"Rita S.","family":"Moreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Bicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felice","family":"Musicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Persichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 M.P.T.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lfs.2019.117093_bb0005","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","article-title":"Guidelines of care for the management of primary cutaneous melanoma","volume":"80","author":"Swetter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.lfs.2019.117093_bb0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur. J. Cancer."},{"key":"10.1016\/j.lfs.2019.117093_bb0015","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.3390\/ijerph15102063","article-title":"Solar radiation exposure and outdoor work: an underestimated occupational risk","volume":"15","author":"Modenese","year":"2018","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.lfs.2019.117093_bb0020","first-page":"1005","article-title":"Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification","volume":"28","author":"Rastrelli","year":"2014","journal-title":"In Vivo."},{"key":"10.1016\/j.lfs.2019.117093_bb0025","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0300-483X(03)00150-1","article-title":"UV-induced skin damage","volume":"189","author":"Ichihashi","year":"2003","journal-title":"Toxicology."},{"key":"10.1016\/j.lfs.2019.117093_bb0030","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00403-009-1001-3","article-title":"Skin photoprotection by natural polyphenols: anti-inflammatory, antioxidant and DNA repair mechanisms","volume":"302","author":"Nichols","year":"2010","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.lfs.2019.117093_bb0035","first-page":"27","article-title":"UV-induced molecular signaling differences in melanoma and non-melanoma skin","author":"Liu-Smith","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.lfs.2019.117093_bb0040","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2003.07.173","article-title":"Chemoprevention of melanoma: an unexplored strategy","volume":"21","author":"Demierre","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0045","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1001\/jamadermatol.2015.2938","article-title":"Association between indoor tanning and melanoma in younger men and women","volume":"152","author":"De Ann","year":"2016","journal-title":"JAMA Dermatology."},{"key":"10.1016\/j.lfs.2019.117093_bb0050","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/ijlh.12426","article-title":"Comparison between different D-dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study","volume":"38","author":"Palareti","year":"2016","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.lfs.2019.117093_bb0055","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40257-016-0221-5","article-title":"Primary and secondary chemoprevention of malignant melanoma","volume":"17","author":"Mounessa","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.lfs.2019.117093_bb0060","series-title":"J.M","author":"Ward","year":"2017"},{"key":"10.1016\/j.lfs.2019.117093_bb0065","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2019.117093_bb0070","author":"Swetter"},{"key":"10.1016\/j.lfs.2019.117093_bb0075","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1200\/JCO.2009.27.2146","article-title":"Immune regulation of cancer","volume":"28","author":"Disis","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejps.2018.10.021","article-title":"PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment","volume":"127","author":"Tang","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.lfs.2019.117093_bb0085","first-page":"406","article-title":"Inflammation and cancer","volume":"4","author":"Kumar","year":"2016","journal-title":"Encycl. Immunobiol."},{"key":"10.1016\/j.lfs.2019.117093_bb0090","doi-asserted-by":"crossref","unstructured":"A.R. Maiuri, H.M. O'Hagan, Interplay Between inflammation and epigenetic changes in cancer, Prog. Mol. Biol. Transl. Sci. 144 (2016) 69\u2013117. doi:https:\/\/doi.org\/10.1016\/bs.pmbts.2016.09.002.","DOI":"10.1016\/bs.pmbts.2016.09.002"},{"key":"10.1016\/j.lfs.2019.117093_bb0095","first-page":"1071","article-title":"Cutaneous melanoma: from pathogenesis to therapy (review)","volume":"52","author":"Leonardi","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0100","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/sj.bjc.6606030","article-title":"Targeting BRAF for patients with melanoma","volume":"104","author":"Arkenau","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2019.117093_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11040465","article-title":"Modelling of protein kinase signaling pathways in melanoma and other cancers","volume":"11","author":"Kunz","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2019.117093_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2016.00095","article-title":"Melanocortin 1 receptor: structure, function, and regulation","volume":"7","author":"Wolf Horrell","year":"2016","journal-title":"Front. Genet."},{"key":"10.1016\/j.lfs.2019.117093_bb0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ad.2016.09.010","article-title":"Estudio descriptivo de costes en melanoma cut\u00e1neo de diferentes estadios","volume":"108","author":"Serra-Arbeloa","year":"2017","journal-title":"Actas Dermosifiliogr."},{"key":"10.1016\/j.lfs.2019.117093_bb0120","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/jcp.2003.015800","article-title":"Genetic pathways to melanoma tumorigenesis","volume":"57","author":"Hussein","year":"2004","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.lfs.2019.117093_bb0125","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1525-1578(10)60684-8","article-title":"Molecular aspects of melanocytic dysplastic nevi","volume":"4","author":"Hussein","year":"2002","journal-title":"J. Mol. Diagnostics."},{"key":"10.1016\/j.lfs.2019.117093_bb0130","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0039-6109(03)00003-3","article-title":"Pathology of malignant melanoma","volume":"83","author":"Liu","year":"2003","journal-title":"Surg. Clin. North Am."},{"key":"10.1016\/j.lfs.2019.117093_bb0135","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1188\/17.CJON.699-709","article-title":"MAPK pathway\u2013targeted therapies: care and management of unique toxicities in patients with advanced melanoma","volume":"21","author":"Rubin","year":"2017","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.lfs.2019.117093_bb0140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bcp.2010.04.029","article-title":"Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail","volume":"80","author":"Inamdar","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2019.117093_bb0145","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00000658-198201001-00005","article-title":"Prognostic factors for melanoma patients with lesions 0.76\u20131.69 mm in thickness. An appraisal of \u201cthin\u201d level IV lesions","volume":"195","author":"Day","year":"1982","journal-title":"Ann. Surg."},{"key":"10.1016\/j.lfs.2019.117093_bb0150","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.sla.0000216771.81362.6b","article-title":"Gender-related differences in outcome for melanoma patients","volume":"243","author":"Scoggins","year":"2006","journal-title":"Ann. Surg."},{"key":"10.1016\/j.lfs.2019.117093_bb0155","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1245\/s10434-013-3100-9","article-title":"Age as a prognostic factor in patients with localized melanoma and regional metastases","volume":"20","author":"Balch","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0160","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2001.19.16.3635","article-title":"Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma","volume":"19","author":"Balch","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0165","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1245\/s10434-009-0353-4","article-title":"Microscopic satellites around a primary melanoma: another piece of the puzzle in melanoma staging","volume":"16","author":"Balch","year":"2009","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0170","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1245\/s10434-018-6689-x","article-title":"Correction to: melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond","volume":"25","author":"Gershenwald","year":"2018","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0175","series-title":"AJCC Cancer Staging Manual","author":"Gershenwald","year":"2017"},{"key":"10.1016\/j.lfs.2019.117093_bb0180","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0185","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lfs.2019.117093_bb0190","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bjc.2015.467","article-title":"Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma","volume":"114","author":"Diem","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lfs.2019.117093_bb0195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies\u2013update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lfs.2019.117093_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40425-019-0569-1","article-title":"Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations","volume":"7","author":"Ascierto","year":"2019","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.lfs.2019.117093_bb0205","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lfs.2019.117093_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-017-0458-3","article-title":"The use of immunotherapy in the treatment of melanoma","volume":"10","author":"Achkar","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0215","first-page":"61","article-title":"Immunotherapy of melanoma","volume":"2","author":"Lugowska","year":"2017","journal-title":"Wspolczesna Onkol."},{"key":"10.1016\/j.lfs.2019.117093_bb0220","first-page":"488","article-title":"Treatment of metastatic melanoma: an overview","volume":"23","author":"Bhatia","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.lfs.2019.117093_bb0225","first-page":"418","article-title":"Immunotherapy of cancer in man","volume":"64","author":"Carter","year":"1976","journal-title":"Am. Sci."},{"key":"10.1016\/j.lfs.2019.117093_bb0230","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.lfs.2019.117093_bb0235","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lfs.2019.117093_bb0240","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.lfs.2019.117093_bb0245","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1590\/abd1806-4841.201756511","article-title":"Cancer immunology and melanoma immunotherapy","volume":"92","author":"Linck","year":"2017","journal-title":"An. Bras. Dermatol."},{"key":"10.1016\/j.lfs.2019.117093_bb0250","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0255","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.coi.2006.01.011","article-title":"Principles and use of anti-CTLA4 antibody in human cancer immunotherapy","volume":"18","author":"Peggs","year":"2006","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.lfs.2019.117093_bb0260","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.lfs.2019.117093_bb0265","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2567.2000.00121.x","article-title":"CD28, CTLA-4 and their ligands: who does what and to whom?","volume":"101","author":"Sansom","year":"2000","journal-title":"Immunology."},{"key":"10.1016\/j.lfs.2019.117093_bb0270","author":"European Society for Medical Oncology"},{"key":"10.1016\/j.lfs.2019.117093_bb0275","author":"Opdivo"},{"key":"10.1016\/j.lfs.2019.117093_bb0280","author":"Keytruda"},{"key":"10.1016\/j.lfs.2019.117093_bb0285","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","article-title":"Cutaneous melanoma, version 2.2019, NCCN Clinical Practice Guidelines in Oncology","volume":"17","author":"Coit","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.lfs.2019.117093_bb0290","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.seminoncol.2017.06.007","article-title":"Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable","volume":"44","author":"Prasad","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0295","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-12-1362","article-title":"Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1","volume":"18","author":"Chen","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2019.117093_bb0300","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","article-title":"A molecular and preclinical comparison of the PD-1\u2013targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab","volume":"44","author":"Fessas","year":"2017","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0305","first-page":"449","article-title":"Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma","volume":"63","author":"Kelderman","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.lfs.2019.117093_bb0310","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2019.117093_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.10.011","article-title":"Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti\u2013programmed death-1 and anti\u2013programmed death ligand 1 trials","volume":"106","author":"Nie","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lfs.2019.117093_bb0320","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lfs.2019.117093_bb0325","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-17-1902","article-title":"Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials","volume":"24","author":"Mushti","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2019.117093_bb0330","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/JTO.0b013e31821b10ab","article-title":"Biostatistics primer: what a clinician ought to know: Hazard ratios","volume":"6","author":"Barraclough","year":"2011","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0335","author":"Camarero"},{"key":"10.1016\/j.lfs.2019.117093_bb0340","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40264-018-0774-8","article-title":"Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer","volume":"42","author":"Baraibar","year":"2019","journal-title":"Drug Saf."},{"key":"10.1016\/j.lfs.2019.117093_bb0345","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0350","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.clinthera.2018.04.003","article-title":"Safety versus tolerability","volume":"40","author":"Shader","year":"2018","journal-title":"Clin. Ther."},{"key":"10.1016\/j.lfs.2019.117093_bb0355","author":"U.S. Department of Health and Human Services"},{"key":"10.1016\/j.lfs.2019.117093_bb0360","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0365","author":"National Cancer Institute"},{"key":"10.1016\/j.lfs.2019.117093_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.lfs.2019.117093_bb0375","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s40265-018-0945-z","article-title":"Metastatic melanoma: recent therapeutic progress and future perspectives","volume":"78","author":"Malissen","year":"2018","journal-title":"Drugs."},{"key":"10.1016\/j.lfs.2019.117093_bb0380","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40257-017-0325-6","article-title":"Advanced melanoma: current treatment options, biomarkers, and future perspectives","volume":"19","author":"Rozeman","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.lfs.2019.117093_bb0385","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lfs.2019.117093_bb0390","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02358-7","article-title":"TNF\u03b1 blockade overcomes resistance to anti-PD-1 in experimental melanoma","volume":"8","author":"Bertrand","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.lfs.2019.117093_bb0395","doi-asserted-by":"crossref","DOI":"10.1038\/s41565-019-0512-0","article-title":"Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators","author":"Conniot","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.lfs.2019.117093_bb0400","doi-asserted-by":"crossref","unstructured":"C. Yin, B. Zhu, T. Zhang, T. Liu, S. Chen, Y. Liu, X. Li, X. Miao, S. Li, X. Mi, J. Zhang, L. Li, G. Wei, Z. Xiang Xu, X. Gao, C. Huang, Z. Wei, C.R. Goding, P. Wang, X. Deng, R. Cui, Pharmacological targeting of STK19 inhibits oncogenic NRAS-driven melanomagenesis, Cell. 176 (2019) 1113\u20131127.e16. doi:https:\/\/doi.org\/10.1016\/j.cell.2019.01.002.","DOI":"10.1016\/j.cell.2019.01.002"},{"key":"10.1016\/j.lfs.2019.117093_bb0405","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/OV.S145532","article-title":"Oncolytic virus and PD-1\/PD-L1 blockade combination therapy","volume":"7","author":"Chen","year":"2018","journal-title":"Oncolytic Virotherapy."},{"key":"10.1016\/j.lfs.2019.117093_bb0410","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40257-013-0025-9","article-title":"Optimal management of metastatic melanoma: current strategies and future directions","volume":"14","author":"Batus","year":"2013","journal-title":"Am. J. Clin. Dermatol."}],"updated-by":[{"DOI":"10.1016\/j.lfs.2020.117433","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,3,15]],"date-time":"2020-03-15T00:00:00Z","timestamp":1584230400000}}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320519310203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320519310203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:44:27Z","timestamp":1793036667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320519310203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":82,"alternative-id":["S0024320519310203"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2019.117093","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2019.117093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117093"}}